Endocrine Abstracts

Introduction: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Studies have shown that patients using FGM test their glucose levels more often than those who use traditional blood glucose testing. Given that a higher rate of glucose testing has showed to improve glycemic control our objective was to describe the change in the glycemic control and time in euglycemic range in patients with FGM and the effect of the number of scans in this control.

Methods and patients: Observational longitudinal clinical study between June and December 2018 in patients with type 1 diabetes (DM1) in which FGM implementation was subsidized.

Results: 69 patients included. Mean age: 16.59±1.23 years, with a mean DM1 evolution time of 6.42±4.79 years. 37.7% women. 47.8% had used FGM before it was subsidized by the public system. After FGM implementation HbA1c levels were reduced from 7.07% to 7.02% although this reduction was not statistically significant. Time in range (between 70 and 140 mg/dL) didn’t change after the implementation (56.61%) but time in hypoglycemia (below 70 mg/dL) was reduced from 9.74 to 8.66% (P=0.394). Among the patients we studied, the more glucose daily data was registered the lower was their HbA1c. Time in range was higher and time in hypoglycemia was reduced when daily scans increased. However, all these improvements didn’t achieve statistical significance (P>0.05)

Conclusions: – In our series, FGM implementation reduced HbA1c levels and also the time patients spent in hypoglycemia, although these improvements were not statistically significant.

– The more scans patients performed and the more glucose daily data was registered, the lower was the HbA1c, the more time they spent in euglycemic range and the less time in hypoglycemia. However all these changes did not reach statistical significance.